相关实验视频
Updated: Jul 3, 2026

06:25
Stereoacuity Improvement using Random-Dot Video Games
Published on: January 14, 2020
14.1K
镜适应治疗是否可以减少空间疏忽并改善功能?
Peii Chen1,2, Kimberly Hreha3, Catrina MacPhee4
1Center for Stroke Rehabilitation Research, Kessler Foundation, West Orange, NJ, United States.
Frontiers in rehabilitation sciences
|February 21, 2025
概括
镜适应治疗 (PAT) 对空间疏忽 (SN) 有希望,但不一致的证据和缺乏标准化的协议阻碍了其有效性. 需要进一步的研究来优化PAT用于临床使用.
科学领域:
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
- 临床心理学 临床心理学
背景情况:
- 由于不一致的元分析,空间疏忽 (SN) 治疗的有效性受到争议.
- 临床数据表明,镜适应治疗 (PAT) 可以减少SN并改善功能.
研究的目的:
- 批判性地审查PAT在SN的治疗效果的证据.
- 识别知识缺口,并建议未来的研究方向.
- 为指导有关PAT的临床决策.
主要方法:
- 利用了NIH的行为干预开发框架阶段模型.
- 批判性地审查了关于空间疏忽的镜适应治疗的现有文献.
- 基于NIH模型的分析研究强调了机制,适应性和可行性.
主要成果:
- 美国国家卫生研究院阶段模型强调了PAT研究中的异质性及其进步中的挑战.
- 关键的治疗参数,如镜强度,强度和评估方法缺乏共识.
- 在不同研究中如何应用和评估PAT存在显著的变化.
结论:
- 进一步的研究对于确定关键机制和建立最佳PAT协议至关重要.
- 在进行新的元分析之前,需要就治疗参数和评估方法达成共识.
- 标准化PAT协议对于推进其临床疗效和实施至关重要.
相关概念视频
Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

